Take Action Now: Shareholders of Unicycive Therapeutics Must Act

Author: Dylan Bailey Updated: 09-29-2025 04:30 PM

Attention Shareholders of Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently the focus of an important notice. Recent developments urge shareholders to pay attention to their rights, especially for those who acquired shares during a specified class period. It’s crucial for shareholders to understand what steps they might need to take.

Understanding Your Rights as a Shareholder

For those who purchased shares of UNCY, it’s encouraged to reach out regarding potential lead plaintiff appointments. Importantly, you don't have to be appointed as a lead plaintiff to recover any losses you might have faced during the class period. Knowing your rights is the first step in addressing any grievances.

What is the Class Period?

The class period for this case spans from March 29, 2024, to June 27, 2025. Individuals who bought shares during this timeframe are particularly urged to file necessary registrations.

Allegations Highlighted in the Class Action

The allegations outline significant concerns regarding materially false and misleading statements made by Unicycive. Key points include claims that the company had overstated its readiness to meet the FDA's manufacturing compliance standards, and they also potentially misrepresented the regulatory prospects tied to their new drug application for oxylanthanum carbonate.

Why This Matters to You

For shareholders, understanding the implications of these allegations can be crucial. If you were misled by the representations made by Unicycive, taking timely action is essential to safeguard your investments.

Critical Deadline Approaching

Make note of the deadline: shareholders must act before October 14, 2025. Registering for this class action is a priority as the date is fast approaching. Failure to act may limit your options in seeking recovery.

Next Steps for Participating Shareholders

Once you have registered, you will gain access to updates regarding the case through a monitoring software tailored for enrolled shareholders. Keeping informed about the status of your case helps you make educated decisions moving forward, ensuring you remain engaged throughout.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as an advocate for shareholders, prioritizing the rights of investors affected by deception or misconduct in business practices. Their commitment is evident through their tireless work to promote transparency in corporate behavior. By choosing them, shareholders tap into a reservoir of expertise and a rich history in dealing with similar cases of class actions.

Contact Information for Further Assistance

If you need assistance or further clarity regarding your shareholder rights or wish to register for potential recovery, don’t hesitate to reach out. Here’s how you can contact The Gross Law Firm:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Frequently Asked Questions

What should I do if I own shares of UNCY?

If you own shares of Unicycive Therapeutics, you should contact The Gross Law Firm to discuss your potential rights and options regarding recovery.

What is the class period for the lawsuit?

The class period for this lawsuit runs from March 29, 2024, to June 27, 2025.

What are the allegations against Unicycive Therapeutics?

The allegations include claims of materially misleading statements and overstatements regarding regulatory compliance and new drug applications.

When is the deadline for action?

The deadline for shareholders to act is October 14, 2025.

Can I participate in the case without being a lead plaintiff?

Yes, shareholders are encouraged to register even if they do not wish to be lead plaintiffs.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.